Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2024322 | 0.83 | CTSB (0.53) | CTSBGABRA1GABRB2HSD11B1LOXL2 | |
| SCHEMBL780568 | 0.80 | CTSB (0.55) | CTSBGABRA1GABRB2HSD11B1LOXL2 | |
| SCHEMBL22780507 | 0.78 | CTSB (0.48) | CTSBGABRA1GABRB2HSD11B1LOXL2 | |
| SCHEMBL330706 | 0.78 | CTSB (0.53) | CTSBGABRA1GABRB2HSD11B1LOXL2 | |
| SCHEMBL10179924 | 0.78 | CTSB (0.53) | CTSBGABRA1GABRB2HSD11B1LOXL2 | |
| SCHEMBL19561701 | 0.78 | PSIP1 (0.45) | CTSBGABRA1GABRB2HSD11B1LOXL2 | |
| SCHEMBL4256900 | 0.76 | PLCG1 (0.54) | CTSBGABRA1GABRB2HSD11B1LOXL2 | |
| SCHEMBL29394818 | 0.76 | CTSB (0.52) | CTSBGABRA1GABRB2HSD11B1LOXL2 | |
| SCHEMBL30096522 | 0.76 | CA2 (0.52) | CTSBHSD11B1LOXL2 | |
| SCHEMBL301742 | 0.76 | CA2 (0.52) | CTSBHSD11B1LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159465-A1 | IMMUNOMODULATOR | HITGEN INC. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159465-A1 | IMMUNOMODULATOR | IL2, IL17A, IL2RA | CTSB 614/4885GABRA1 530/4885GABRB2 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.